This result can be explained by the opinion that activation of JAK1 and NOTCH1 pathways might cooperate in T-ALL pathogenesis and progression [23, 30], encouraging the studies on combination of several targeted therapies in refractory/relapse cases.. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.